Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
Gufic Biosciences faces critical compliance exposure under SEBI BRSR Core Expansion, with a maximum compliance risk score of 10.0/10 and unknown EPR applicability creating potential enforcement and delisting risk if reporting obligations are not clarified and met. The company's missing Scope 1 and Scope 2 emissions data—despite operating pharmaceutical manufacturing facilities—suggests either incomplete measurement infrastructure or inadequate disclosure, risking regulatory censure under BRSR P6 environmental standards. With ₹82 crore revenue and negligible estimated compliance costs (₹0 crore), the financial exposure is primarily reputational and regulatory rather than capital-intensive; however, addressing emissions quantification and EPR compliance gaps should be prioritized to avoid SEBI enforcement action. The medium ESG risk score (5.3/10) is driven by unresolved compliance and EPR gaps rather than operational carbon intensity, making governance and disclosure remediation the primary financial mitigation lever.
Source: Gufic Biosciences Limited BRSR Filing, FY 2024-2025. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.